Conventional therapeutic options have limited impact on MPN symptoms: Insights from a prospective analysis of the MPN-SAF TSS
Robyn M. Scherber(Blueprint Medicines (United States)), Ruben A. Mesa(Atrium Health Wake Forest Baptist), Francesco Passamonti(University of Milan), Frank Stegelmann(University Hospital Ulm), Pablo Muxí(Hospital Británico), Gunnar Birgegård(Uppsala University Hospital), Jean‐Christophe Ianotto(Inserm), Heike L. Pahl(University Medical Center Freiburg), Ayalew Tefferi(Mayo Clinic), Francisco Cervantes(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Carlos Besses(Hospital Del Mar), Dolores Hernández‐Maraver(Centre Hospitalier Universitaire de Grenoble), Andreas Reiter(Heidelberg University), Thomas Lehmann(University of Basel), Deepti Radia(St Thomas' Hospital), Harry C. Schouten, Norman Maldonado(University of Puerto Rico System), Jean‐Yves Cahn, Konstanze Doehner(University Hospital Ulm), Alessandro M. Vannucchi(Azienda Ospedaliero-Universitaria Careggi), Claire Harrison(Guy's and St Thomas' NHS Foundation Trust), Jan Samuelsson(Karolinska University Hospital), Peter Johansson(Linköping University), F. Boyer, Björn Andréasson(NU Hospital Group), Alessandro Rambaldi(Ospedale Papa Giovanni XXIII), Federico Sackmann(Centre Hospitalier Universitaire de Grenoble), Peter A.W. te Boekhorst(Erasmus MC), G Étienne, M Greiesshammer, Stefanie Slot(Amsterdam UMC Location Vrije Universiteit Amsterdam), Maria L Ferarri(Centre Hospitalier Universitaire de Grenoble), Karin Bonatz(Centre Hospitalier Universitaire de Grenoble), Suzan Commandeur(Leiden University), Sonja Zweegman(Vrije Universiteit Amsterdam), Giovanni Barosi(Policlinico San Matteo Fondazione), Amylou C. Dueck(Mayo Clinic in Arizona), A Fuentes, Lydia Roy(Centre Hospitalier Universitaire de Poitiers), T Barbui, Jean‐Jacques Kiladjian(Délégation Paris 5)
Haematologica
January 1, 2012
Cited by 6
Related Papers
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
|Blood|2009|4.4k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k